ResearcherBengbu Medical CollegeActive in the last 2 years

Kai Chen

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 6 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper

Papers 1

FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degradation. Co-author DOI 10.1038/s41419-024-06425-y ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jia Ma · 1 shared paper, 2024 · strength 0.19
- Paper FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degrad… DOI 10.1038/s41419-024-06425-y ↗
Jun Xia · 1 shared paper, 2024 · strength 0.19
- Paper FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degrad… DOI 10.1038/s41419-024-06425-y ↗
Shangshang Hu · 1 shared paper, 2024 · strength 0.19
- Paper FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degrad… DOI 10.1038/s41419-024-06425-y ↗
Zhiwei Peter Wang · 1 shared paper, 2024 · strength 0.19
- Paper FBXO31 is upregulated by METTL3 to promote pancreatic cancer progression via regulating SIRT2 ubiquitination and degrad… DOI 10.1038/s41419-024-06425-y ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.